The Cell and Gene Podcast: The Future Of iPSCs With BlueRock Therapeutics’ CEO Seth Ettenberg

BlueRock Therapeutics’ President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company’s Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.

Click Here To Listen

Related News

Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025
Press Releases

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan

December 17, 2025
Press Releases

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 7, 2025
Press Releases

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel 

September 22, 2025